Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER⁺/HER2^- Breast Cancer.

There was a highly significant association between baseline levels of c-PARP and incidence of CCCA at 14 weeks with letrozole+palbociclib ( P < 0.001) but no such association with letrozole alone ( P = 0.98); interaction P = 0.01.

also in 132,142 other papers

In tumors not amplified for CCND1 , higher baseline CCND1 expression was associated with a greater chance of CCCA although this only showed a trend to significance for letrozole+palbociclib ( P = 0.02; overall population P = 0.07).

also in 53,322 other papers

The only other substantial relationship was with CCNE1 levels that at baseline showed a strong trend to association with no achievement of CCCA for letrozole alone ( P = 0.02) but not for letrozole+palbociclib (Supplementary Fig.

also in 5,725 other papers